Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 16Other solid neoplasm 9Gastrointestinal 3Sarcoma 1

Conditions

Colorectal Neoplasms 2Pancreatic Neoplasms 1Neoplasms 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × sotorasib × Gastrointestinal × Clear all
NCT07563738 2026-05-04

TEADCO

Orion Corporation, Orion Pharma

Phase 1/2 Recruiting
229 enrolled
GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT05198934 2026-04-27

CodeBreak300

Amgen

Phase 3 Completed
160 enrolled 1 FDA
Gastrointestinal

Colorectal Neoplasms

NCT06252649 2026-04-24

CodeBreaK 301

Amgen

Phase 3 Recruiting
450 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡